IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

PHASE2CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

May 4, 2011

Primary Completion Date

December 24, 2013

Study Completion Date

December 2, 2024

Conditions
Prostate CancerProstatic Neoplasm
Interventions
DRUG

abiraterone acetate in combination with prednisone

Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.

Trial Locations (45)

Unknown

Homewood

Huntsville

Tucson

Los Angeles

San Diego

San Francisco

Aurora

Denver

Aventura

Orange City

Atlanta

Evanston

Galesburg

Glenview

Melrose Park

Fort Wayne

Jeffersonville

New Orleans

Baltimore

Rockville

Boston

Lansing

Omaha

Lawrenceville

Albany

Brooklyn

Buffalo

Garden City

New York

Poughkeepsie

Staten Island

Chapel Hill

Raleigh

Cincinnati

Cleveland

Lancaster

Philadelphia

Pittsburgh

Greenville

Myrtle Beach

Nashville

Arlington

Houston

Seattle

Milwaukee

Sponsors
All Listed Sponsors
lead

Janssen Biotech, Inc.

INDUSTRY

NCT01314118 - IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen | Biotech Hunter | Biotech Hunter